On December 23, "Yeju Medical," a portfolio company invested in by Share Investment—the sub-fund backed by the mother fund managed by Yuanhe Chenchun—was listed on the Hong Kong Stock Exchange under the stock code: 6929.HK.

Founded in 2000 and headquartered in Hong Kong, China, Yiju Medical is a globally positioned, innovative medical device company specializing in vascular intervention. With manufacturing and R&D facilities in China, the Netherlands, and the United States, the company has established branches across the globe. To date, Yiju Medical boasts over 40 products approved for sale worldwide—ranging from semi-compliant balloons and specialized catheters to scored balloons and non-compliant balloons—catering to every major treatment step involved in both PCI and PTA procedures.

Yiju Medical is also actively expanding its business into the fields of neurovascular intervention and structural heart disease, with products currently in various stages of development—such as valve-plasty balloon catheters, balloon-expandable heart valves, next-generation heart valves, neuroballoons, neuromicrocatheters, and neurosealing balloons.

Yejv Medical is deeply rooted in the global market, with products sold in over 70 countries and regions. It is currently the only medical device manufacturer headquartered in China that ranks among the top six in key overseas PCI balloon markets, including Japan, Europe, and the United States.

Meanwhile, Yiju Medical's product performance has reached world-class standards, and its diversified product portfolio ensures comprehensive coverage across key areas of vascular intervention. Additionally, the company’s high-value-added pipeline products are steadily being introduced to the market, providing a sustained engine for growth.